Please login to the form below

Not currently logged in
Email:
Password:

Common ICU drug blocks cardiovascular effects of cocaine

An intensive care unit drug commonly used as a sedative may have the ability to counteract the effects of cocaine on the human cardiovascular system, according to a US study

An intensive care unit drug commonly used as a sedative may have the ability to counteract the effects of cocaine on the human cardiovascular system, according to a US study.

Doctors at UT Southwestern Medical Center published details of their discovery in the 14 August issue of the Journal of the American College of Cardiology.

Precedex (dexmedetomidine), which is manufactured by US-based Orion, was found to lower the heart rate and blood pressure in a clinical trial involving 22 volunteers who had taken a small dose of the drug. Researchers also found that the drug reduced sympathetic nerve activity in the subjects who had taken cocaine.

Dr Wanpen Vongpatanasin, the study's senior author, said: "We have found that cocaine's effects on the cardiovascular system can be reversed by dexmedetomidine, which is currently approved by the FDA for anaesthetic purposes in operating rooms or intensive care units."

The new treatment would prove superior to the current regimen of nitroglycerin, sedatives and blood pressure medications used to treat cocaine-induced medical disorders, because dexmedetomidine also reverses cocaine's adverse effects on heart rate, blood pressure and vascular resistance.

The study authors said further research was needed to see if dexmedetomidine could be used to treat acute cocaine overdose in accident and emergency units.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics